Ann Kalita

Molecular Biology Consortium — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index2.9kcitations23works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Histone Deacetylase Inhibitors Research(19), Protein Degradation and Inhibitors(17), Epigenetics and DNA Methylation(6), Peptidase Inhibition and Analysis(4), Cancer-related Molecular Pathways(3)

Publications23 total

Data from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103)
Bioorganic & Medicinal Chemistry Letters·2008· 7 citedOpen Access
Discovery of <i>N</i>-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor
Journal of Medicinal Chemistry·2008· 108 citedOpen Access
Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay
Clinical Cancer Research·2008· 99 citedOpen Access
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Blood·2008· 234 citedOpen Access
Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
Journal of Clinical Oncology·2008· 118 cited
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
Molecular Cancer Therapeutics·2008· 333 citedOpen Access
4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors
Bioorganic & Medicinal Chemistry Letters·2007· 13 citedOpen Access
Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors
Bioorganic & Medicinal Chemistry Letters·2007· 35 citedOpen Access
Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine in patients with refractory solid tumors
2007
Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: Novel classes of histone deacetylase inhibitors
Bioorganic & Medicinal Chemistry Letters·2006· 29 citedOpen Access
(2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors
Bioorganic & Medicinal Chemistry Letters·2003· 28 citedOpen Access
Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors
Journal of Medicinal Chemistry·2003· 71 citedOpen Access
Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
PubMed·2002· 84 cited
Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically
Molecular and Cellular Biology·1999· 700 cited
page 1 of 2Next →

Frequent Co-authors

Zuomei Li(19), Jeffrey M. Besterman(18), Marielle Fournel(15), Marie-Claude Trachy-Bourget(15), Pu Yan(14), Oscar Moradei(14), Aihua Lu(12), Jubrail Rahil(12), Claire Bonfils(10), Jianhong Liu(10), Marie‐France Robert(10), Jinru Wang(10), Daniel Delorme(9), A. Robert MacLeod(9), Silvana Leit(8), Sylvie Fréchette(8), Nancy Z. Zhou(7), Jeffrey Gillespie(7), Hélène Ste-Croix(7), Sylvain Lefèbvre(7)